Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

Published:2021-01 Issue:1 Volume:22 Page:74-84
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Toi Masakazu,Imoto Shigeru,Ishida Takanori,Ito Yoshinori,Iwata Hiroji,Masuda Norikazu,Mukai Hirofumi,Saji Shigehira,Shimizu Akira,Ikeda Takafumi,Haga Hironori,Saeki Toshiaki,Aogi Kenjiro,Sugie Tomoharu,Ueno Takayuki,Kinoshita Takayuki,Kai Yuichiro,Kitada Masahiro,Sato Yasuyuki,Jimbo Kenjiro,Sato Nobuaki,Ishiguro Hiroshi,Takada Masahiro,Ohashi Yasuo,Ohno Shinji

Funder

Taiho Pharmaceutical

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

2. Endocrine therapy for early breast cancer: updated review;Tremont;Ochsner J,2017

3. Genomic characterization of metastatic breast cancers;Bertucci;Nature,2019

4. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future;Spring;Lancet,2020

5. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial);Ohashi;Breast Cancer Res Treat,2010

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts;Translational Oncology;2024-10

2. Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches;European Journal of Cancer;2024-09

3. Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients;International Journal of Clinical Oncology;2024-08-23

4. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

5. Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer;Clinical Breast Cancer;2024-07